Related Experiment Video
Updated: May 29, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Computational Exploration of a Diverse Flavonoid Library for Targeted Allosteric Inhibition of AKT1 in Cancer Therapy
Mohd Rehan1,2, Ishfaq A Sheikh3,2, Mohd Suhail3,2
1King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia mrtahir@kau.edu.sa mrehan786@gmail.com.
Background/Aim:
AKT serine/threonine kinase 1 (AKT1) is an established therapeutic target in cancer therapy due to its role in promoting cell survival and proliferation. This study aimed to identify potential allosteric inhibitors of AKT1 from a large flavonoid library using computational methods.
Materials And Methods:
A computational screening of a comprehensive flavonoid library to identify novel allosteric inhibitors targeting the AKT1 allosteric site was performed. Molecular docking identified compounds with favorable binding interactions and the top 10 were selected for binding pose analysis. Molecular dynamics simulations for 200 ns were further employed to assess the stability of the highest-ranked compound.
Results:
The study proposed 10 flavonoids as potential allosteric AKT1 inhibitors. The docking analysis highlighted critical interactions between the 10 flavonoids and AKT1, with residues such as Trp-80, Ile-84, Tyr-272, Arg-273 and Asp-292 playing significant roles in binding stability. Trp-80 emerged as a pivotal residue, consistently forming the highest number of non-bonding contacts across most compounds, corresponding with prior studies that identified it as essential for allosteric inhibition. The highest-ranked flavonoid, CID 108790283, demonstrated the strongest binding affinity, with a binding energy of -10.64 kcal/mol, 56 non-bonding contacts, and a hydrogen bond. Molecular dynamics simulations further confirmed the stability of this flavonoid within the allosteric site, exhibiting minimal conformational fluctuation throughout the 200-ns simulation.
Conclusion:
This computational investigation identified 10 flavonoids with strong interaction profiles and stable binding within the allosteric site of AKT1, suggesting their potential as novel AKT1 inhibitors. These findings provide a basis for further experimental studies to validate their efficacy in cancer treatment.
Insights
This study computationally identified 10 flavonoids as potential allosteric inhibitors of AKT1 (AKT serine/threonine kinase 1), a key target in cancer. The top compound showed strong binding and stability, paving the way for new cancer therapies.
Area of Science:
- Computational chemistry
- Drug discovery
- Oncology
Background:
- AKT serine/threonine kinase 1 (AKT1) is crucial for cancer cell survival and proliferation.
- AKT1 is a validated therapeutic target for cancer treatment.
- Identifying novel allosteric inhibitors is essential for effective cancer therapy.
Purpose of the Study:
- To computationally screen a flavonoid library for novel allosteric AKT1 inhibitors.
- To identify compounds with favorable binding interactions and stable binding poses within the AKT1 allosteric site.
Main Methods:
- Computational screening of a large flavonoid library against AKT1.
- Molecular docking to predict binding affinities and interactions.
- Molecular dynamics simulations to assess the stability of top-ranked compounds.
Main Results:
- Ten flavonoids were identified as potential allosteric AKT1 inhibitors.
- Key residues (Trp-80, Ile-84, Tyr-272, Arg-273, Asp-292) were critical for binding.
- The top flavonoid (CID 108790283) exhibited strong binding affinity (-10.64 kcal/mol) and stable interactions.
- Molecular dynamics confirmed the stability of the lead compound in the allosteric site.
Conclusions:
- This study computationally identified promising flavonoid-based allosteric AKT1 inhibitors.
- The findings support further experimental validation for potential cancer therapeutics.
- The identified compounds offer a new avenue for developing targeted cancer treatments.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Allosteric Regulation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

